Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 30, 2017 08:30 ET | Source: Advaxis

GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer

PRINCETON, N.J., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that an abstract on data...
January 25, 2017 08:00 ET | Source: Advaxis

New Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported

PRINCETON, N.J., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today pointed to research published in the...
January 09, 2017 08:00 ET | Source: Advaxis

Advaxis Provides 2017 Business Outlook

PRINCETON, N.J., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today issued its 2017 business outlook to...
December 12, 2016 08:15 ET | Source: Advaxis

Discussion on Advaxis’ ADXS-NEO, ADXS-HOT Programs Held During the International Congress on Immunotherapies in Cancer

Presentation detailed Advaxis’ bacterial vector system, new preclinical program in hotspots PRINCETON, N.J., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage...
December 07, 2016 08:00 ET | Source: Advaxis

Advaxis to Present Data at ImVacS-Immunization and Vaccine Summit on Use of Detoxified Listeriolysin O (dtLLO) as an Effective Adjuvant in Vaccine Formulations

PRINCETON, N.J., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that preclinical data on the...
November 15, 2016 08:00 ET | Source: Advaxis

Advaxis to Present at the Jefferies 2016 London Healthcare Conference

PRINCETON, N.J., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel O’Connor,...
November 11, 2016 07:30 ET | Source: Advaxis

Advaxis to Present Phase 1 Combination Data and New Preclinical Data Using AXAL at Upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting

Phase 1 AXAL and durvalumab combination trial shows safety and tolerability in cervical and HPV+ head and neck cancerPreclinical data demonstrate synergistic antitumor effects of AXAL combined with a...
October 24, 2016 08:00 ET | Source: Advaxis

Advaxis Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2

Data in 50 patients with recurrent metastatic carcinoma of the cervix demonstrates a 52% increase in 12-month overall survival rate PRINCETON, N.J., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc....
October 20, 2016 07:30 ET | Source: Advaxis

Advaxis Initiates Combination Portion of Phase 1/2 Study with Merck

KEYNOTE-046 study to evaluate KEYTRUDA® in combination with ADXS-PSA Advaxis begins screening patients for Phase 3 AIM2CERV study in cervical cancer PRINCETON, N.J., Oct. 20, 2016 (GLOBE...
October 13, 2016 08:00 ET | Source: Advaxis

Advaxis to Receive $2.5M through the New Jersey Economic Development Authority NOL Program

PRINCETON, N.J., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, has received preliminary approval for a $2.7...